A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas Academic Article uri icon

Overview

MeSH Major

  • Brain Neoplasms
  • Carboxymethylcellulose Sodium
  • Glioma
  • Interferon Inducers
  • Neoplasm Recurrence, Local
  • Poly I-C
  • Polylysine

abstract

  • This phase II study was designed to determine the objective response rate and 6-month progression free survival of adult patients with recurrent supratentorial anaplastic glioma when treated with the immune modulator, polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC). This was an open-labeled, single arm phase II study. Patients were treated with poly-ICLC alone. Patients may have had treatment for no more than two prior relapses. Treatment with poly-ICLC continued until tumor progression. Fifty five patients were enrolled in the study. Ten were ineligible after central review of pathology. Eleven percent of patients (5 of 45) had a radiographic response. Time to progression was known for 39 patients and 6 remain on treatment. The estimated 6-month progression free survival was 24%. The median survival time was 43 weeks. Poly-ICLC was well tolerated, but there was no improvement in 6-month progression free survival compared to historical database nor was there an encouraging objective radiographic response rate. Based on this study, poly-ICLC does not improve 6moPFS in patients with recurrent anaplastic gliomas but may be worth further study in combination with agents such as temozolomide.

publication date

  • January 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3104130

Digital Object Identifier (DOI)

  • 10.1007/s11060-008-9705-3

PubMed ID

  • 18850068

Additional Document Info

start page

  • 183

end page

  • 9

volume

  • 91

number

  • 2